News

Published on 8 May 2024 on Zacks via Yahoo Finance

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down


Article preview image

Bio-Rad Laboratories, Inc. BIO posted first-quarter 2024 adjusted earnings per share (EPS) of $2.29, beating the Zacks Consensus Estimate by 12.3%. However, the bottom line declined 31.4% from the prior-year quarter’s levels.

The quarter’s adjustments eliminate the impacts of certain non-recurring items like the amortization of purchased intangibles, Restructuring costs, gains/losses from the change in the fair market value of equity securities and gains/losses on equity-method investments.

NYSE.BIO price evolution
NYSE.BIO-B price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Bio-Rad Laboratories fair value estimate...

Simply Wall St. · via Yahoo Finance 29 Nov 2024

Bio-Rad Laboratories, Inc. (BIO): A Bull Case Theory

We came across a bullish thesis on Bio-Rad Laboratories, Inc. (BIO) on Substack by Stock Analysis...

Insider Monkey · via Yahoo Finance 24 Nov 2024

Earnings call: Bio-Rad reports solid Q3 2024 growth, net income surges By...

The company's net income saw a significant surge to $653 million, largely due to a substantial ga...

Investing.com 31 Oct 2024

Bio-Rad Laboratories Inc (BIO) Q3 2024 Earnings Call Highlights: Strong Clinical...

Net Sales: $650 million, a 2.8% increase from Q3 2023. Life Science Group Sales: $261 million,...

GuruFocus.com · via Yahoo Finance 31 Oct 2024

Bio-Rad Laboratories, Inc. (BIO): Should You Invest In This Organ Transplant and...

We recently compiled a list of the 10 Best Organ Transplant and Diagnosis Stocks To Buy Now. In t...

Insider Monkey · via Yahoo Finance 19 Aug 2024

Here's What Analysts Are Forecasting For Bio-Rad Laboratories, Inc. (NYSE:BIO) After Its...

The first-quarter results for Bio-Rad Laboratories, Inc. (NYSE:BIO) were released last week, maki...

Simply Wall St. via Yahoo Finance 10 May 2024

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down

Bio-Rad Laboratories, Inc. BIO posted first-quarter 2024 adjusted earnings per share (EPS) of $2....

Zacks via Yahoo Finance 8 May 2024

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2024 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2024 Earnings Call Transcript May 7, 2024 Bio-Rad Labora...

Insider Monkey via Yahoo Finance 8 May 2024

Bio-Rad Laboratories Inc (BIO) Q1 2024 Earnings: Mixed Results Amid Market Challenges

Revenue: Reported $610.8 million, a decrease of 9.8% year-over-year, falling short of estimates o...

GuruFocus.com via Yahoo Finance 7 May 2024

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

(NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Olema Pharmaceuticals, Inc. (NASDAQ: OLM...

WTNH-TV New Haven 3 May 2024